Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants uri icon

abstract

  • OBJECTIVE: To assess the reversibility of the elevation of serum creatinine levels in patients with diabetes after 5 years of continuous on-trial fenofibrate therapy. RESEARCH DESIGN AND METHODS: An on-drug/off-drug ancillary study to the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial to investigate posttrial changes in serum creatinine and cystatin C. Eligible participants were recruited into a prospective, nested, three-group study based on retrospective on-trial serum creatinine levels: fenofibrate case subjects (n = 321, >/= 20% increase after 3 months of therapy); fenofibrate control subjects (n = 175, /= 20%) returned to the same level of renal function as participants receiving placebo while participants who had

publication date

  • 2012